Lumateperone Monotherapy Versus Usual Antidepressant Treatment for First-Episode Depression (LUMA-FIRST)
Efficacy and Safety of Lumateperone Monotherapy Versus Antidepressant-Based Treatment as Usual in First-Episode Major Depressive Disorder: An Exploratory, Randomized, Assessor-Blinded Trial
This study will compare lumateperone monotherapy with usual antidepressant treatment in adults experiencing their first lifetime episode of major depressive disorder. Use of lumateperone alone for this form of depression is investigational.
The study will enroll 134 adults aged 18 to 65 years who have clinically significant depression and have not received medication to treat their current depressive episode. Participants will be assigned by chance to one of two groups. One group will receive lumateperone 42 mg once daily as the only scheduled medicine used to treat depression. The other group will receive sertraline or escitalopram, selected by the treating psychiatrist. Treatment will last eight weeks.
Both groups will receive the same scheduled clinical contacts, information about depression, and access to psychological care. A trained assessor who does not know the assigned treatment will measure depressive symptoms at the beginning of the study and after 2, 4, and 8 weeks.
The main outcome will be improvement in depressive symptoms at week 8. Other outcomes will include response, remission, unwanted effects, stopping medication because of unwanted effects, and the need to switch or add another depression treatment. There will be weekly contact during treatment and a safety follow-up at week 10. Treatment may be changed at any time when clinically necessary. Recruitment will begin only after the required ethics and regulatory approvals have been obtained.
調査の概要
詳細な説明
STUDY PURPOSE AND DESIGN This investigator-initiated, single-center, exploratory superiority trial will compare an initial treatment strategy of lumateperone monotherapy with antidepressant-based treatment as usual in first-episode major depressive disorder. Sultan Qaboos University is the sponsor. The proposed clinical site is Sultan Qaboos University Hospital, University Medical City, Muscat, Oman. The unique institutional protocol identifier is 35. The study will recruit 134 adults, with 67 assigned to each group.
The comparison concerns medication-naive patients experiencing their first lifetime depressive episode. Lumateperone monotherapy for unipolar major depressive disorder is investigational. Approval of lumateperone for other indications does not establish the benefit-risk balance of this regimen in the proposed population. The full protocol, informed consent, and local regulatory assessment will address this uncertainty and the availability of established antidepressant treatment outside the study.
DIAGNOSIS AND RECRUITMENT Diagnosis will be confirmed through a structured diagnostic assessment and a lifetime psychiatric history. Available medical records and collateral information obtained with consent will support assessment of first-episode status and exclusion of bipolar and psychotic disorders. No established antidepressant will be withdrawn solely to enable participation. Participants will be suitable for outpatient treatment and have a baseline Montgomery-Asberg Depression Rating Scale (MADRS) score of at least 24.
RANDOMIZATION AND MASKING An independent researcher will prepare a computer-generated 1:1 allocation sequence using randomly varying balanced block sizes. An independent coordinator will retain the sequence and release allocation after eligibility, informed consent, and baseline assessments are complete. The clinician's intended usual-care antidepressant will be selected and documented before randomization for each participant.
Participants and prescribers will know the allocation. MADRS assessments will be performed by trained assessors who remain unaware of allocation and are independent of treatment decisions. Medication review and adverse-event assessment will occur separately. Participants will be asked to avoid disclosing treatment to assessors. Accidental unmasking will be documented. Treatment groups will be coded for the statistician until the primary analysis is completed.
INTERVENTIONS The experimental group will receive lumateperone 42 mg orally once daily in the evening, with or without food, for eight weeks. No antidepressant, additional antipsychotic, or mood stabilizer will be routinely prescribed with lumateperone to treat depression. Routine dose titration or an alternative lower-dose efficacy regimen is not planned. Temporary interruption or discontinuation will be permitted when clinically indicated.
The comparator group will receive either sertraline or escitalopram, selected according to clinical suitability, patient preference, and contraindications. Sertraline will usually start at 50 mg daily, with clinician-directed adjustment within 50 to 200 mg daily. Escitalopram will usually start at 10 mg daily, with adjustment up to 20 mg daily when appropriate. Lower starting doses and product-specific dose restrictions will be observed when clinically indicated. Both medicines will not be assigned together as the planned comparator treatment. Prescribing will follow the locally authorized product information and pharmacy review.
Both groups will receive comparable clinical contact, psychoeducation, adherence support, and access to psychological care. Psychological treatments and all relevant concomitant medicines will be recorded. Clinically necessary treatment changes and rescue interventions will remain available in both groups.
ASSESSMENTS Clinic assessments will take place at baseline and weeks 2, 4, and 8. Telephone or video safety contacts will occur at weeks 1, 3, 5, 6, and 7. A final scheduled safety contact will occur at week 10. Additional contact will be arranged when needed. MADRS ratings will be collected at baseline and weeks 2, 4, and 8. The same language version will be used throughout follow-up. Rater training and access to the approved Arabic and English instruments will be arranged before recruitment.
The primary outcome is change in MADRS score from baseline to week 8. Secondary outcomes are response, remission, treatment-emergent adverse events, discontinuation of the initial medication because of adverse effects, and use of rescue treatment. Participants who discontinue or change medication will be encouraged to remain in follow-up.
SAFETY AND RESCUE TREATMENT Baseline assessment will include medical and psychiatric history, medication reconciliation, weight, vital signs, appropriate laboratory testing, electrocardiography, and pregnancy testing when applicable. The full protocol will specify laboratory assessments and stopping rules before recruitment. Safety reviews will address suicidal thoughts and behavior, emerging mania or hypomania, sedation, dizziness, orthostatic symptoms, akathisia, other abnormal movements, and metabolic changes. Glucose, lipid, and weight monitoring will be included.
Urgent reassessment will be arranged for suicidal intent, mania, psychosis, substantial deterioration, serious adverse reactions, or inability to remain safely in outpatient care. Established treatment will not be delayed to preserve the assigned regimen. At week 4, persistent clinically significant symptoms with less than 20% MADRS improvement will trigger senior psychiatric review and a discussion of optimization or rescue treatment. This is a proposed study decision rule and does not restrict earlier clinical intervention.
An independent safety physician will review serious or unexpected events. Formal monitoring arrangements and the need for a data monitoring committee will be agreed with the sponsor and ethics committee. Serious adverse events will be reported according to institutional and regulatory requirements. Ongoing adverse events will be followed to resolution or clinical stabilization, including after week 10 when necessary.
At week 8, ongoing clinical treatment will be agreed with each participant and the treating psychiatrist. Appropriate access to continuing treatment or a supervised transition to another treatment must be arranged before recruitment. Finishing the research assessments will not automatically end clinical care.
SAMPLE SIZE The target is 134 randomized participants, with 67 per group. A two-sided independent two-sample calculation with alpha 0.05 and 80% power requires approximately 53 evaluable participants per group to detect a standardized difference of 0.55. Allowance for approximately 20% unavailable primary outcomes gives 67 participants per group. The assumed difference is a planning value and has not been established for lumateperone monotherapy against active antidepressant care in first-episode depression. The study is exploratory and is not designed to demonstrate noninferiority or equivalence. A nonsignificant difference will not establish comparable efficacy.
STATISTICAL ANALYSIS The primary analysis will follow the intention-to-treat principle. Week-8 MADRS scores will be compared using analysis of covariance adjusted for baseline MADRS score. The adjusted between-group difference, 95% confidence interval, and two-sided p value will be reported. A significance level of 0.05 will apply to the primary outcome.
Data collected after medication discontinuation, switching, or rescue treatment will remain part of the primary analysis. The estimand is the effect of assignment to the two initial treatment strategies under the trial's clinical management arrangements. Missing primary outcomes will be addressed by multiple imputation under a missing-at-random assumption, including allocation, baseline severity, available intermediate scores, and relevant predictors of missingness. Complete-case and missing-not-at-random sensitivity analyses will be prespecified in the statistical analysis plan.
Response, remission, rescue treatment, and discontinuation will be reported as proportions with between-group differences and confidence intervals. Secondary analyses will be exploratory. Any supplementary analysis restricted to participants who maintained the assigned regimen will be interpreted cautiously because remaining on treatment is affected by response and tolerability. No interim efficacy analysis is planned.
MEDICATION SUPPLY AND APPROVALS Lumateperone is planned to be purchased from Johnson & Johnson or an authorized supplier, subject to availability, procurement arrangements, and applicable permissions in Oman. This is a planned purchase rather than a confirmed supply, funding, or collaboration agreement. Johnson & Johnson is not listed as a sponsor or collaborator on the basis of the planned purchase alone. Pharmacy will manage receipt, storage, dispensing, and accountability.
Ethics review has not yet been requested. Recruitment will begin only after ethics approval and all required institutional and regulatory permissions are in place. Registration does not constitute permission to start the trial.
研究の種類
入学 (推定)
段階
- フェーズ 4
連絡先と場所
研究連絡先
- 名前:Mohammed Al Alawi, MD, PhD, MBA, MRCPsych
- 電話番号:+96824141511
- メール:m.alalawi2@squ.edu.om
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age 18 to 65 years and ability to provide written informed consent.
- First lifetime major depressive episode meeting DSM-5-TR criteria for major depressive disorder without psychotic features, confirmed by a structured diagnostic assessment.
- MADRS total score of at least 24 at screening and baseline.
- No previous pharmacological treatment for the current depressive episode and no current antidepressant, antipsychotic, or mood-stabilizing medication.
- Clinical suitability for outpatient treatment and for either randomized treatment strategy.
- Ability to complete assessments in Arabic or English, using the same language throughout follow-up.
Exclusion Criteria:
- Any previous lifetime major depressive episode.
- History of mania, hypomania, bipolar disorder, schizophrenia-spectrum disorder, or another primary psychotic disorder.
- Current depressive episode with psychotic features, mixed features, or catatonia.
- Immediate suicide risk or another condition requiring urgent inpatient treatment, electroconvulsive therapy, or an intervention incompatible with randomization.
- Substance-induced depression, depression attributable to another medical condition, or an active substance use disorder that would interfere with treatment or assessment.
- A psychiatric or medical condition requiring continuation or immediate initiation of medication incompatible with either assigned treatment strategy.
- Hypersensitivity to lumateperone or its formulation; moderate or severe hepatic impairment; or a moderate or strong CYP3A4 inhibitor or a CYP3A4 inducer incompatible with the fixed 42 mg lumateperone regimen. Contraindications to both proposed usual-care antidepressants also exclude participation.
- Clinically significant unstable medical illness or electrocardiographic abnormalities that make participation unsafe.
- Pregnancy, breastfeeding, planned pregnancy during the trial, or inability to meet the pregnancy-testing and reproductive-safety requirements approved in the full protocol.
- Participation in another interventional study that could affect treatment or outcome assessment.
- Inability to provide informed consent or complete essential study procedures.
Stable anxiety disorders and stable medical comorbidities may be permitted when diagnosis, safety, and assessment are not compromised. Passive suicidal thoughts require individualized assessment and do not automatically exclude an otherwise safe outpatient participant. No established treatment will be stopped solely to permit enrollment.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Lumateperone Monotherapy
Participants will receive lumateperone 42 mg orally once daily in the evening for eight weeks. It will be the only scheduled medicine used to treat depression. No antidepressant, additional antipsychotic, or mood stabilizer will be routinely added. Both groups will receive comparable clinical reviews, psychoeducation, and access to psychological care. Interruption, discontinuation, or rescue treatment will be allowed when clinically required. Starting another depression treatment will be recorded as rescue treatment and a departure from the assigned monotherapy regimen. Outcome follow-up will continue whenever consent permits. |
Lumateperone (Caplyta) 42 mg orally once daily in the evening, with or without food, for eight weeks as pharmacological monotherapy for depression. Routine titration or escalation is not planned. Participants requiring an alternative dose for hepatic impairment or interacting medication will be excluded from this fixed-dose study. Temporary interruption or discontinuation is permitted for safety or intolerance. |
|
アクティブコンパレータ:Antidepressant-Based Treatment as Usual
Participants will receive either sertraline or escitalopram selected by their psychiatrist. The intended usual-care antidepressant will be documented before randomization. Treatment will be adjusted according to response, tolerability, contraindications, and locally authorized prescribing information. Both groups will receive comparable clinical reviews, psychoeducation, and access to psychological care. Clinically necessary treatment changes and rescue interventions will be permitted and recorded. |
One of the two usual-care alternatives. Sertraline will usually be started at 50 mg orally once daily and adjusted by the treating psychiatrist within 50 to 200 mg daily according to response and tolerability. A lower starting dose may be used when clinically indicated. Dosing will follow locally authorized product information and pharmacy review. It is an alternative to escitalopram, rather than a planned combination. One of the two usual-care alternatives. Escitalopram will usually be started at 10 mg orally once daily and may be adjusted up to 20 mg daily when clinically appropriate. Lower starting doses or maintenance limits will follow age, comorbidity, tolerability, locally authorized product information, and pharmacy review. It is an alternative to sertraline, rather than a planned combination. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change From Baseline in Montgomery-Asberg Depression Rating Scale Total Score at Week 8
時間枠:Baseline and week 8
|
The Montgomery-Asberg Depression Rating Scale (MADRS) contains 10 clinician-rated items, each scored from 0 to 6. Total scores range from 0 to 60; higher scores indicate greater depressive symptom severity. A trained assessor unaware of allocation will administer the scale. Change is the week-8 score minus the baseline score, with negative values indicating improvement. The primary comparison is the baseline-adjusted between-group difference. |
Baseline and week 8
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of Participants Achieving Depression Response
時間枠:Week 8
|
Response is defined as a reduction of at least 50% from baseline in the MADRS total score. MADRS scores range from 0 to 60, with higher scores indicating greater depressive symptom severity. |
Week 8
|
|
Proportion of Participants Achieving Depression Remission
時間枠:Week 8
|
Remission is defined as a MADRS total score of 10 or lower at week 8. MADRS scores range from 0 to 60, with higher scores indicating greater depressive symptom severity. |
Week 8
|
|
Number of Participants With at Least One Treatment-Emergent Adverse Event
時間枠:From the first dose through week 10
|
A treatment-emergent adverse event is a new medical or psychiatric event, or worsening of a pre-existing condition, after initiation of the assigned medication. Events will be collected in both groups by structured questioning, clinical review, and relevant medical records. Severity, seriousness, suspected relatedness, and management will be recorded. Ongoing events will continue to receive clinical follow-up when necessary. |
From the first dose through week 10
|
|
Number of Participants Discontinuing the Initially Assigned Medication Because of Adverse Effects
時間枠:From treatment initiation through week 8
|
Permanent discontinuation of lumateperone or the initially selected antidepressant because of an adverse effect will be recorded. The medication, reason, and date will be documented. Temporary interruptions will be recorded separately and will not count as permanent discontinuation. |
From treatment initiation through week 8
|
|
Number of Participants Receiving Rescue Treatment
時間枠:From randomization through week 8
|
Rescue treatment is the initiation of an additional treatment for depression or switching the initially assigned medication because of inadequate benefit, deterioration, or intolerance. Hospitalization, electroconvulsive therapy, and other urgent interventions will also be recorded when applicable. Dose adjustment of the initially assigned medication alone will not count as rescue treatment. Indication and timing will be documented. |
From randomization through week 8
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Mohammed Al Alawi, MD, PhD, MBA, MRCPsych、Sultan Qaboos University
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 35
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。